Latest news

• Sanofi exits R&D pact with Alnylam on rare disease

  Alprolix – and the takeover of Belgian biotech Ablynx last year to claim rights to acquired thrombotic thrombocytopenic purpura (aTTP) therapy Cablivi (caplacizumab).

• Sanofi extends growth spurt thanks to Genzyme, Dupixent

  US approval of Cablivi adds to good news. Sanofi has put a long run of decline caused by patent losses in its rear view mirror, with rare disease unit Genzyme and ... from Cablivi (caplacizumab) for acquired thrombotic thrombocytopenic purpura (aTTP),

• Sanofi gets US okay for $270,000 blood disorder drug Cablivi

  Analysts at Jefferies have suggested that Cablivi could be a game-changer in aTTP treatment and generate sales of up to $500m a year. ... Cablivi works by neutralising the blood glycoprotein von Willebrand factor (vWF), which is involved in blood clotting

• Sanofi's Darzalex rival scores in myeloma trial

  Key developments for the company this year include the market development of Cablivi, which is approved in the EU and awaiting a final FDA nod, as well as the expected approval

• As France protests, Sanofi takes axe to 670 jobs

  dermatitis therapy Dupixent (dupilumab), checkpoint inhibitor Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC) and Cablivi(caplacizumab) for acquired thrombotic thrombocytopenic purpura.